CAR-T cell therapy + mosunetuzumab + polatuzumab

This is a combination therapy comprised of three distinct modalities for the treatment of aggressive relapsed or refractory non-Hodgkin lymphomas, specifically large B-cell lymphoma (LBCL). The regimen includes: - CAR-T cell therapy, which utilizes genetically modified autologous T lymphocytes expressing a chimeric antigen receptor targeting CD19 on malignant B cells, resulting in selective tumor cell lysis. - Mosunetuzumab, a bispecific monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, redirecting T-cell cytotoxicity against malignant B cells. - Polatuzumab vedotin, an antibody-drug conjugate composed of an anti-CD79b monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E, which disrupts microtubules in targeted B cells. This combination is explored in trials (e.g., NCT05260957, NCT2022-06935) aiming to improve outcomes for patients with relapsed/refractory aggressive B-cell lymphomas, including those who have failed prior therapies. Each drug targets different mechanisms in B-cell malignancy: CAR-T for direct cell-mediated cytotoxicity, mosunetuzumab for T-cell recruitment, and polatuzumab vedotin for targeted delivery of cytotoxic payloads.[5][7]